Salivary Proteomics Reveals Protein Changes During Multiple Sclerosis Treatment - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Salivary Proteomics Reveals Protein Changes During Multiple Sclerosis Treatment

  • November 16, 2026

  • 2 min

Share

Clinical Scorecard: Salivary Proteomics Reveals Protein Changes During Multiple Sclerosis Treatment

At a Glance

CategoryDetail
ConditionRelapsing-remitting multiple sclerosis (RRMS)
Key MechanismsSalivary protein patterns were associated with innate immunity, neutrophil degranulation, cytokine signaling, programmed cell death, and protein folding.
Target Population66 patients with RRMS starting a new disease-modifying therapy and 31 healthy controls; 40 patients provided a follow-up sample.
Care SettingExploratory proteomics study using saliva samples collected before treatment and after six months of therapy.

Key Highlights

  • Mass spectrometry identified 1,305 salivary proteins; 623 met criteria for statistical analysis.
  • Before treatment, 116 proteins differed in abundance between patients with RRMS and healthy controls; 54 differed after six months of therapy.
  • Some protein patterns persisted, some shifted toward control levels, and others differed only at follow-up.
  • A 50-protein panel distinguished controls, pretreatment patients, and follow-up patients within the study cohort.
  • The authors state that the panel is not ready for diagnostic or clinical use.

Guideline-Based Recommendations

Diagnosis

  • The study does not establish salivary proteomics as a diagnostic test for RRMS.

Management

  • The study reports protein changes during disease-modifying therapy but does not establish these changes as evidence of treatment response.

Monitoring & Follow-up

  • Saliva was evaluated as a noninvasive sample for studying molecular changes over time.
  • The authors call for larger multicenter studies comparing salivary signatures with clinical findings, imaging, and established fluid biomarkers.

Risks

  • The 50-protein panel is not ready for diagnostic or clinical use.

Patient & Prescribing Data

The study included 66 patients with RRMS before starting a new therapy; 40 provided a second sample after six months. It also included 31 healthy controls.

After six months, 54 proteins remained different between patients and controls, compared with 116 before treatment. The authors interpreted this as changing salivary protein patterns, not proof of treatment response.

Clinical Best Practices

  • Interpret the reported protein panel as exploratory and not as a diagnostic or clinical tool.
  • Do not infer treatment response from the observed reduction in proteins differing between patients and controls.
  • Further validation should compare salivary signatures with clinical findings, imaging, and established fluid biomarkers.

Related Resources & Content

    Original Source(s)

    Related Content